A Phase 4 interventional study of placebo and alprazolam XR in Panic Disorder, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 3 sites in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Panic Disorder with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Panic Disorder · United States.
Among the 109 studies in Panic Disorder with a site in United States, this one is the 92nd largest by enrollment of the 94 interventional ones that give a count, is one of 9 that started in 2004, is one of 18 in phase 4, and was the 40th registered.
270 studies on the registry are indexed under Panic Disorder; 37 are open to participants now.
Browse Panic Disorder studies →9 of the 109 studies in Panic Disorder with a site in United States are open now. Recruiting first, the newest first:
Andrew Wiese · Sites in United States
Ages 7–17
Bradley Hospital · Sites in United States
Ages 5–18
Ohio State University · Sites in United States
Ages 18+
Georgetown University · Sites in United States
Ages 18–65
University of Michigan · Sites in United States
Ages 18–24
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Panic Disorder studies recruiting now, 8 (33%) set no upper age limit and 15 (63%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 13 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 15 · Phase 3 8 · Phase 4 18
First in 1994; this study’s year is marked. 9 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 77 across 215 interventional studies indexed under Panic Disorder.
Median enrollment 69 across the 94 interventional studies, 54 across the 13 observational. Of the 89 that completed or were terminated, 29 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 109 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 7 studies filed under Panic Disorder — fewer than ten, so there is no comparison to draw.
6 of the studies in Panic Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05467683Jasper A. SmitsCO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy | 2026-12-01 |
| NCT07028216Georgetown UniversityMindful Self-compassion for Anxiety and Depression: Impact of Delivery Method | 2026-12-17 |
| NCT01075672Massachusetts General HospitalOutcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals | 2027-01 |
| NCT05117255University of MinnesotaValidating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity | 2027-03-01 |
| NCT05427708University of Texas at AustinRespiratory Training in the Treatment of Transdiagnostic Pathological Anxiety | 2027-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 109 studies in Panic Disorder with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term (6-month) efficacy, safety, and tolerability of alprazolam XR in adolescents with panic disorder.
Due to recruitment difficulties in this adolescent population, the clinical program for alprazolam XR was cancelled and this study was terminated on 1 September 2004. There were no safety concerns that led to this decision.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: placebo
Drug: alprazolam XR
Patients continued taking the matching placebo that they were taking when they completed Study A6131002 (oral tablets taken once daily).
Patients continued taking the same dosage of alprazolam that they were taking when they completed Study A6131002 (oral tablets taken once daily (1-6mg)); patients taking less than 6 mg/day who failed to show a satisfactory clinical response since the previous visit, and who were free of dose-limiting adverse events, could have their dosage titrated upward by 1 mg/day; upward daily dosage titration of 1 mg was allowed every 7 days, up to a maximum daily dosage of 6 mg/day; patients who were unable to tolerate the previous dosage level of alprazolam XR could have their daily dosage reduced.
Also known as: Xanax XR
Baseline-to-peak Physician Withdrawal Checklist change score during taper off Alprazolam
Time frame: Week 24 (taper baseline), Weeks 25-29, and end of taper visit
The incidence of treatment-emergent adverse events during 6 months of treatment with alprazolam XR
Time frame: Weeks 6, 8, 12, 16, 20, and 24
Endpoint change from baseline in Digit Symbol-Coding Test, immediate recall, and delayed recall
Time frame: Week 24
Endpoint change from baseline in Hamilton Anxiety Rating scale
Time frame: Weeks 12 and 24
Endpoint change compared with baseline in the Panic Disorder Severity Scale - Adolescent Version total and item scores
Time frame: Weeks 12 an 24
Endpoint compared with baseline for Clinical Global Impression (CGI)-Improvement scale
Time frame: Weeks 12 and 24
Endpoint change compared with baseline in CGI-Severity score
Time frame: Weeks 12 and 24
Endpoint compared with baseline in Pediatric Quality of Life, Enjoyment, and Satisfaction Questionnaire improvement score
Time frame: Weeks 12 and 24
Descriptive estimates of the persistence of safety events and adverse events
Time frame: Week 24
The record gives a start of Jul 2004 and a completion of Sep 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alprazolam
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →